Risk  ||| S:0 E:5 ||| NN
assessment  ||| S:5 E:16 ||| NN
and  ||| S:16 E:20 ||| CC
prognostic  ||| S:20 E:31 ||| JJ
factors  ||| S:31 E:39 ||| NNS
for  ||| S:39 E:43 ||| IN
mould-related  ||| S:43 E:57 ||| JJ
diseases  ||| S:57 E:66 ||| NNS
in  ||| S:66 E:69 ||| IN
immunocompromised  ||| S:69 E:87 ||| JJ
patients  ||| S:87 E:96 ||| NNS
Invasive  ||| S:96 E:105 ||| JJ
fungal  ||| S:105 E:112 ||| JJ
diseases  ||| S:112 E:121 ||| NNS
are  ||| S:121 E:125 ||| VBP
important  ||| S:125 E:135 ||| JJ
causes  ||| S:135 E:142 ||| NNS
of  ||| S:142 E:145 ||| IN
morbidity  ||| S:145 E:155 ||| NN
and  ||| S:155 E:159 ||| CC
mortality  ||| S:159 E:169 ||| NN
in  ||| S:169 E:172 ||| IN
immunocompromised  ||| S:172 E:190 ||| JJ
patients ||| S:190 E:198 ||| NNS
.  ||| S:198 E:200 ||| .
Patients  ||| S:200 E:209 ||| NNS
with  ||| S:209 E:214 ||| IN
haematological  ||| S:214 E:229 ||| JJ
malignancies  ||| S:229 E:242 ||| NN
and  ||| S:242 E:246 ||| CC
solid  ||| S:246 E:252 ||| JJ
cancers ||| S:252 E:259 ||| NNS
,  ||| S:259 E:261 ||| ,
as  ||| S:261 E:264 ||| RB
well  ||| S:264 E:269 ||| RB
as  ||| S:269 E:272 ||| IN
those  ||| S:272 E:278 ||| DT
with  ||| S:278 E:283 ||| IN
allogeneic  ||| S:283 E:294 ||| JJ
haematopoietic  ||| S:294 E:309 ||| NNS
stem  ||| S:309 E:314 ||| VBP
cell  ||| S:314 E:319 ||| NN
and  ||| S:319 E:323 ||| CC
solid  ||| S:323 E:329 ||| JJ
organ  ||| S:329 E:335 ||| NN
transplants ||| S:335 E:346 ||| NNS
,  ||| S:346 E:348 ||| ,
are  ||| S:348 E:352 ||| VBP
at  ||| S:352 E:355 ||| IN
high  ||| S:355 E:360 ||| JJ
risk  ||| S:360 E:365 ||| NN
of  ||| S:365 E:368 ||| IN
developing  ||| S:368 E:379 ||| VBG
such  ||| S:379 E:384 ||| PDT
an  ||| S:384 E:387 ||| DT
infection ||| S:387 E:396 ||| NN
.  ||| S:396 E:398 ||| .
Many  ||| S:398 E:403 ||| JJ
fungi  ||| S:403 E:409 ||| NNS
can  ||| S:409 E:413 ||| MD
cause  ||| S:413 E:419 ||| VB
invasive  ||| S:419 E:428 ||| JJ
disease ||| S:428 E:435 ||| NN
,  ||| S:435 E:437 ||| ,
with  ||| S:437 E:442 ||| IN
Aspergillus  ||| S:442 E:454 ||| NNP
spp.  ||| S:454 E:459 ||| NNP
and  ||| S:459 E:463 ||| CC
Candida  ||| S:463 E:471 ||| NNP
spp.  ||| S:471 E:476 ||| NNP
being  ||| S:476 E:482 ||| VBG
the  ||| S:482 E:486 ||| DT
prevalent  ||| S:486 E:496 ||| FW
fungal  ||| S:496 E:503 ||| FW
pathogens  ||| S:503 E:513 ||| FW
infecting  ||| S:513 E:523 ||| FW
susceptible  ||| S:523 E:535 ||| JJ
patients ||| S:535 E:543 ||| NNS
.  ||| S:543 E:545 ||| .
During  ||| S:545 E:552 ||| IN
the  ||| S:552 E:556 ||| DT
past  ||| S:556 E:561 ||| JJ
few  ||| S:561 E:565 ||| JJ
years ||| S:565 E:570 ||| NNS
,  ||| S:570 E:572 ||| ,
rare  ||| S:572 E:577 ||| JJ
moulds  ||| S:577 E:584 ||| NNS
( ||| S:584 E:585 ||| -LRB-
for  ||| S:585 E:589 ||| IN
example  ||| S:589 E:597 ||| NN
Zygomycetes  ||| S:597 E:609 ||| NNP
and  ||| S:609 E:613 ||| CC
Fusarium  ||| S:613 E:622 ||| NNP
spp. ||| S:622 E:626 ||| NNP
)  ||| S:626 E:628 ||| -RRB-
have  ||| S:628 E:633 ||| VBP
come  ||| S:633 E:638 ||| VBN
into  ||| S:638 E:643 ||| IN
focus  ||| S:643 E:649 ||| NN
as  ||| S:649 E:652 ||| IN
the  ||| S:652 E:656 ||| DT
cause  ||| S:656 E:662 ||| NN
of  ||| S:662 E:665 ||| IN
devastating  ||| S:665 E:677 ||| JJ
clinical  ||| S:677 E:686 ||| JJ
disease ||| S:686 E:693 ||| NN
.  ||| S:693 E:695 ||| .
This  ||| S:695 E:700 ||| DT
review  ||| S:700 E:707 ||| NN
aims  ||| S:707 E:712 ||| VBZ
to  ||| S:712 E:715 ||| TO
analyse  ||| S:715 E:723 ||| VB
environmental  ||| S:723 E:737 ||| JJ
factors  ||| S:737 E:745 ||| NNS
and  ||| S:745 E:749 ||| CC
parameters  ||| S:749 E:760 ||| NNS
related  ||| S:760 E:768 ||| VBN
to  ||| S:768 E:771 ||| TO
impairment  ||| S:771 E:782 ||| VB
of  ||| S:782 E:785 ||| IN
the  ||| S:785 E:789 ||| DT
immune  ||| S:789 E:796 ||| JJ
system  ||| S:796 E:803 ||| NN
that  ||| S:803 E:808 ||| WDT
are  ||| S:808 E:812 ||| VBP
thought  ||| S:812 E:820 ||| VBN
to  ||| S:820 E:823 ||| TO
favour  ||| S:823 E:830 ||| VB
the  ||| S:830 E:834 ||| DT
onset  ||| S:834 E:840 ||| NN
of  ||| S:840 E:843 ||| IN
invasive  ||| S:843 E:852 ||| JJ
mould  ||| S:852 E:858 ||| JJ
infections ||| S:858 E:868 ||| NNS
.  ||| S:868 E:870 ||| .
Some  ||| S:870 E:875 ||| DT
moulds  ||| S:875 E:882 ||| NNS
are  ||| S:882 E:886 ||| VBP
quite  ||| S:886 E:892 ||| RB
common  ||| S:892 E:899 ||| JJ
among  ||| S:899 E:905 ||| IN
all  ||| S:905 E:909 ||| DT
categories  ||| S:909 E:920 ||| NNS
of  ||| S:920 E:923 ||| IN
patients ||| S:923 E:931 ||| NNS
,  ||| S:931 E:933 ||| ,
while  ||| S:933 E:939 ||| IN
others  ||| S:939 E:946 ||| NNS
appear  ||| S:946 E:953 ||| VBP
to  ||| S:953 E:956 ||| TO
be  ||| S:956 E:959 ||| VB
limited  ||| S:959 E:967 ||| VBN
to  ||| S:967 E:970 ||| TO
a  ||| S:970 E:972 ||| DT
given  ||| S:972 E:978 ||| VBN
subset  ||| S:978 E:985 ||| NN
of  ||| S:985 E:988 ||| IN
patients ||| S:988 E:996 ||| NNS
,  ||| S:996 E:998 ||| ,
such  ||| S:998 E:1003 ||| JJ
as  ||| S:1003 E:1006 ||| IN
allogeneic  ||| S:1006 E:1017 ||| JJ
haematopoietic  ||| S:1017 E:1032 ||| NNS
stem  ||| S:1032 E:1037 ||| VBP
cell  ||| S:1037 E:1042 ||| NN
or  ||| S:1042 E:1045 ||| CC
solid  ||| S:1045 E:1051 ||| JJ
organ  ||| S:1051 E:1057 ||| NN
transplant  ||| S:1057 E:1068 ||| NN
recipients ||| S:1068 E:1078 ||| NNS
.  ||| S:1078 E:1080 ||| .
In  ||| S:1080 E:1083 ||| IN
addition  ||| S:1083 E:1092 ||| NN
to  ||| S:1092 E:1095 ||| TO
an  ||| S:1095 E:1098 ||| DT
exploration  ||| S:1098 E:1110 ||| NN
of  ||| S:1110 E:1113 ||| IN
factors  ||| S:1113 E:1121 ||| NNS
that  ||| S:1121 E:1126 ||| IN
predispose  ||| S:1126 E:1137 ||| JJ
patients  ||| S:1137 E:1146 ||| NNS
to  ||| S:1146 E:1149 ||| TO
the  ||| S:1149 E:1153 ||| DT
acquisition  ||| S:1153 E:1165 ||| NN
of  ||| S:1165 E:1168 ||| IN
an  ||| S:1168 E:1171 ||| DT
invasive  ||| S:1171 E:1180 ||| JJ
mould  ||| S:1180 E:1186 ||| JJ
infection ||| S:1186 E:1195 ||| NN
,  ||| S:1195 E:1197 ||| ,
prognostic  ||| S:1197 E:1208 ||| JJ
factors  ||| S:1208 E:1216 ||| NNS
that  ||| S:1216 E:1221 ||| WDT
help  ||| S:1221 E:1226 ||| VBP
to  ||| S:1226 E:1229 ||| TO
predict  ||| S:1229 E:1237 ||| VB
the  ||| S:1237 E:1241 ||| DT
eventual  ||| S:1241 E:1250 ||| JJ
outcome  ||| S:1250 E:1258 ||| NN
of  ||| S:1258 E:1261 ||| IN
these  ||| S:1261 E:1267 ||| DT
infections  ||| S:1267 E:1278 ||| NNS
are  ||| S:1278 E:1282 ||| VBP
identified ||| S:1282 E:1292 ||| VBN
.  ||| S:1292 E:1294 ||| .
